AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6891929
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg b.d. (P)
Trial: 6891929
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg b.d. (T)
Trial: 27669638
Drug: Probiotic capsule
RxNorm normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsule
Trial: 27065056
Drug: P2Y12-receptor specific
RxNorm normalized name: PACIFIC OYSTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2Y12-receptor specific assay (ADPtest HS)
Trial: 24685414
Drug: Standard Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Regimen + individualized homeopathic medicine (SR + H)
Trial: 19039231
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy to maintain strict normoglycemia (below 110 mg/dl)
Trial: 19039231
Drug: Strict blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict blood glucose control with intensive insulin therapy
Trial: 18088216
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) delivered in school or clinic settings by trained clinicians
Trial: 15333734
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (SPI) with high isoflavone content (mean intake 96 mg/d)
Trial: 15333734
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (SPI) with low isoflavone content (mean intake 6 mg/d)
Trial: 11441210
Drug: Constraint-induced (CI)
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced (CI) aphasia therapy
Trial: 2541985
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (6.6 g/bar, average consumption 31.7 g/day)
Trial: 21118735
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 20 mg BID (group A)
Trial: 21118735
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 40 mg BID (group B)
Trial: 21118735
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Rabeprazole 10 mg BID (group C)
Trial: 16368293
Drug: Methotrexate (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (7.5 mg once a week, n = 35)
Trial: 15753186
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil plus different doses of vitamin E for 3 months
Trial: 8454221
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine
Trial: 3773599
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dipyrone, pitofenone and fenpipramide (control)
Trial: 29516425
Drug: Topical fusidic
RxNorm normalized name: fusidate Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fusidic acid (2%) and recombinant human interferon after ALA-PDT
Trial: 19016941
Drug: BIMS (Brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIMS (Brief Interview of Mental Status) administered by research assistants
Trial: 19016941
Drug: BIMS (Brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIMS (Brief Interview of Mental Status) administered by facility nurses
Trial: 12778045
Drug: Ethical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethical treatment and motivation of participants
Trial: 8780817
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy (ZDV/ddI)
Trial: 8780817
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) therapy (monotherapy or alternating)
Trial: 1600993
Drug: gallopamil 150
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil 150 mg daily for 4 weeks
Trial: 1600993
Drug: nifedipine 60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 60 mg daily for 4 weeks
Trial: 6541198
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: rifampin 600 mg twice weekly, prothionamide 500 mg, and dapsone (DDS) 100 mg daily for six months, followed by 100 mg DDS daily for another six months
Trial: 24793093
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine (IV BUP)
Trial: 24793093
Drug: Intranasal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buprenorphine (IN BUP)
Trial: 19680659
Drug: 900 ml
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 ml of low-density barium sulphate (LDB) (group C)
Trial: 19680659
Drug: 900 ml
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 ml of low-density barium sulphate (LDB) (groups C, D, E)
Trial: 19680659
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral contrast agent (group A)
Trial: 19680659
Drug: 900 ml
RxNorm normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 ml of water (group B)
Trial: 18559644
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oral oseltamivir every 24 h (group 1)
Trial: 18559644
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oseltamivir every 48 h combined with 500 mg probenecid four times a day (group 2)
Trial: 18559644
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3)
Trial: 12215687
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.2 mg/ml
Trial: 12215687
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.4 mg/ml
Trial: 12215687
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.2 mg/ml and 0.4 mg/ml
Trial: 10667741
Drug: Haloperidol or
RxNorm normalized name: haloperidol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol or another conventional antipsychotic
Trial: 7541769
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GH (0.125 IU/kg/week)
Trial: 7541769
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose GH (0.5 IU/kg/week)
Trial: 2116083
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg/day for 6 months)
Trial: 2116083
Drug: Control (non-medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-medication group)
Trial: 877639
Drug: Spray containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray containing a local anesthetic plus an antiseptic agent
Trial: 28333029
Drug: Diluted hyaluronidase
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diluted hyaluronidase (8 IU/mL)
Trial: 28333029
Drug: Normal hyaluronidase
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Normal hyaluronidase (80 IU/mL)
Trial: 25843912
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of 5-aminolevulinic acid (5-ALA)
Trial: 25843912
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg of 5-aminolevulinic acid (5-ALA)
Trial: 23816561
Drug: Sinusoidal chronomodulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinusoidal chronomodulated infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Trial: 23816561
Drug: Flat intermittent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat intermittent constant rate infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Trial: 21356150
Drug: Six servings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six servings of low glycaemic index (LGI) foods daily
Trial: 21356150
Drug: Eight servings
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight servings of low glycaemic index (LGI) foods daily
Trial: 17405995
Drug: Chemotherapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (standard chemotherapy, 87% received cyclophosphamide, methotrexate, and 5-fluorouracil; 11% received anthracycline-containing regimens)
Trial: 17405995
Drug: Chemotherapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (standard chemotherapy)
Trial: 8787073
Drug: Drug (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (specific drug not mentioned)
Trial: 6131857
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 150 mg ranitidine
Trial: 6131857
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 400 mg cimetidine
Trial: 23715669
Drug: Colloid administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid administration
Trial: 31067347
Drug: Intervention arm
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention arm (screening with prostate-specific antigen and digital rectal examination)
Trial: 19927136
Drug: Pill count
RxNorm normalized name: Pill Counting Tray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill count
Trial: 19927136
Drug: Both MEMS
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both MEMS and pill count
Trial: 15957843
Drug: Aiyishu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aiyishu Injection (AYSI), 50 ml by intrathoracic and another 50 ml by intravenous injection, repeated after 3 days.
Trial: 15957843
Drug: Chemotherapeutic agent
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic agent or interleukin-2 (IL-2)
Trial: 12048138
Drug: Bezafibrate treatment
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate treatment for 3 months
Trial: 7573262
Drug: Pyridoxine hydrochloride,
RxNorm normalized name: Pyridoxine Hydrochloride, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine hydrochloride, 30 mg per day
Trial: 2253535
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg four times a day
Trial: 29057618
Drug: Bococizumab 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bococizumab 0.25 mg/kg
Trial: 29057618
Drug: Bococizumab 1
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 1 mg/kg
Trial: 29057618
Drug: Bococizumab 3
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 3 mg/kg
Trial: 29057618
Drug: Bococizumab 6
RxNorm normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 6 mg/kg
Trial: 29057618
Drug: Bococizumab 6
RxNorm normalized name: brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bococizumab 6 mg/kg (all three doses)
Trial: 26228480
Drug: Bolstered usual
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolstered usual care plus a family-level economic strengthening intervention (Suubi-Maka treatment arm)
Trial: 21292625
Drug: Drug Burden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Burden Index (DBI)
Trial: 17914954
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg for 2 days and 1 hour before the test
Trial: 11809341
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg tibolone (Livial) daily for 12 months
Trial: 10052765
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing + 2% minocycline gel (S+Min)
Trial: 10052765
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing + 25% metronidazole gel (S+Met)
Trial: 7485940
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of blood salvage and three units of PABT
Trial: 7422399
Drug: Phenobarbital (PB)
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (PB) 100 mg at bedtime for the last few weeks of pregnancy
Trial: 7422399
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no phenobarbital treatment)
Trial: 7422399
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with moderate or marked jaundice (bilirubin > 12 mg/dl)
Trial: 31526875
Drug: CR4056 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR4056 (100 mg bid for women; 200 mg bid for men)
Trial: 26016861
Drug: High egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High egg (HE) meal (150 g scrambled whole eggs)
Trial: 26016861
Drug: Low egg
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low egg (LE) meal (75 g scrambled whole eggs)
Trial: 23958768
Drug: Computerized decision
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized decision support system for ADHD diagnosis and treatment guidelines.
Trial: 15302282
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist + recombinant LH (75 IU/day)
Trial: 15302282
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist alone (C)
Trial: 11536410
Drug: Velocity-dependent method
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velocity-dependent method (16-18 mL of gadolinium)
Trial: 11536410
Drug: High-dose method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose method (38 mL of gadolinium)
Trial: 9491873
Drug: Oral 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 17beta-estradiol (E2), 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle) for 12 months, then E2, 2 mg daily, combined with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for 3 months
Trial: 3380504
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of meperidine
Trial: 30548928
Drug: Multimedia surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimedia surgical care tour (4 educational videos and automated reminders to take medications)
Trial: 28545493
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily testing with standard feedback (glucose values reported immediately)
Trial: 28545493
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily testing with enhanced patient feedback (glucose values reported immediately plus automated tailored feedback messaging)
Trial: 25437509
Drug: Supervised therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised therapy (n=89)
Trial: 25437509
Drug: Home-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based therapy (n=36)
Trial: 25437509
Drug: Supervised therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised therapy (high performers, n=70)
Trial: 25437509
Drug: Home-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based therapy (high performers, n=38)
Trial: 25437509
Drug: Supervised therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised therapy and Home-based therapy (WOMAC subscales)
Trial: 22789392
Drug: interpositional intra-oral
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: interpositional intra-oral autogenous bone graft
Trial: 19591067
Drug: Oral Naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Naltrexone (NTX) treatment 3 times per week for 12 weeks
Trial: 19591067
Drug: Study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication (NTX)
Trial: 16406224
Drug: DTPa-IPV booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTPa-IPV booster vaccine
Trial: 15291288
Drug: Cyclic nonplatinum
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic nonplatinum chemotherapy
Trial: 11702325
Drug: Propofol (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (5‐10 mg/kg/h) and remifentanil (0.125‐1.0 microgram/kg/min)
Trial: 9389861
Drug: alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 20 micrograms kg‐1, propofol 2.5 mg kg‐1 and vecuronium 0.1 mg kg‐1
Trial: 9389861
Drug: thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thiopentone 5 mg kg‐1 and suxamethonium 1 mg kg‐1
Trial: 3286173
Drug: PPA 75
RxNorm normalized name: Guaifenex PPA 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA 75 mg SR
Trial: 3286173
Drug: PPA SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPA SR 75 mg with caffeine 200 mg
Trial: 28707491
Drug: Omega-3 supplement
RxNorm normalized name: Systane Vitamin Omega-3 Supplement Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplement (1g fish oil)
Trial: 21177517
Drug: Acceptance-based behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based behavior therapy (ABBT)
Trial: 18377622
Drug: Serum enriched
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum enriched in marine compounds
Trial: 18377622
Drug: Cream formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream formulation
Trial: 18377622
Drug: Lotion and
RxNorm normalized name: KIT, LOTION AND CREAM, EMOLLIENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion and cream formulations
Trial: 18377622
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (after stopping treatment)
Trial: 17313803
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg/d for 7 days before surgery
Trial: 17313803
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of celecoxib 200 mg/d and octreotide 100 microg injected subcutaneously for 7 days before surgery
Trial: 17313803
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anti‐tumor medicine before GC resection)
Trial: 12682082
Drug: Eplerenone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (50 to 200 mg daily)
Trial: 12682082
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10 mg daily)
Trial: 10067694
Drug: Combined, short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined, short schedule group (Co-S) - DTaP and PRP-T vaccines reconstituted immediately prior to injection at 3, 4 and 5 months of age
Trial: 10067694
Drug: Associated, long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Associated, long schedule group (As-L) - DTaP + PRP-T at separate sites at 2, 4 and 6 months